JP2007023038A - 落屑を促進するための尿素化合物の使用 - Google Patents
落屑を促進するための尿素化合物の使用 Download PDFInfo
- Publication number
- JP2007023038A JP2007023038A JP2006192113A JP2006192113A JP2007023038A JP 2007023038 A JP2007023038 A JP 2007023038A JP 2006192113 A JP2006192113 A JP 2006192113A JP 2006192113 A JP2006192113 A JP 2006192113A JP 2007023038 A JP2007023038 A JP 2007023038A
- Authority
- JP
- Japan
- Prior art keywords
- urea
- compound
- formula
- composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010040844 Skin exfoliation Diseases 0.000 title claims abstract description 56
- 230000035618 desquamation Effects 0.000 title claims abstract description 46
- 230000001737 promoting effect Effects 0.000 title claims abstract description 11
- 239000004202 carbamide Substances 0.000 title claims description 27
- -1 urea compound Chemical class 0.000 title description 17
- 239000000203 mixture Substances 0.000 claims abstract description 115
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 239000002537 cosmetic Substances 0.000 claims abstract description 37
- 239000004365 Protease Substances 0.000 claims abstract description 35
- 108091005804 Peptidases Proteins 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 48
- 210000003491 skin Anatomy 0.000 claims description 48
- 210000000434 stratum corneum Anatomy 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 31
- 102000035195 Peptidases Human genes 0.000 claims description 30
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 claims description 20
- 239000003410 keratolytic agent Substances 0.000 claims description 19
- 235000018102 proteins Nutrition 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 210000002615 epidermis Anatomy 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 14
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 13
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 210000004400 mucous membrane Anatomy 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 230000002797 proteolythic effect Effects 0.000 claims description 12
- 108091005508 Acid proteases Proteins 0.000 claims description 11
- 108010076876 Keratins Proteins 0.000 claims description 11
- 102000011782 Keratins Human genes 0.000 claims description 11
- 230000015556 catabolic process Effects 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 102000004882 Lipase Human genes 0.000 claims description 7
- 108090001060 Lipase Proteins 0.000 claims description 7
- 239000004367 Lipase Substances 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 206010021198 ichthyosis Diseases 0.000 claims description 7
- 235000019421 lipase Nutrition 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 208000001840 Dandruff Diseases 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 4
- 210000004761 scalp Anatomy 0.000 claims description 4
- AWNNECGZCPBURJ-UHFFFAOYSA-N 3-(2-hydroxyethyl)-1,1-bis(2-hydroxypropyl)urea Chemical compound CC(O)CN(CC(C)O)C(=O)NCCO AWNNECGZCPBURJ-UHFFFAOYSA-N 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000000021 stimulant Substances 0.000 claims description 3
- OFVBXCOYANJMRT-UHFFFAOYSA-N (1-hydroxy-2-methylpropan-2-yl)urea Chemical compound OCC(C)(C)NC(N)=O OFVBXCOYANJMRT-UHFFFAOYSA-N 0.000 claims description 2
- OSPRSYHXEUOSQA-UHFFFAOYSA-N 1,1-bis(2-hydroxyethyl)-3,3-dimethylurea Chemical compound CN(C)C(=O)N(CCO)CCO OSPRSYHXEUOSQA-UHFFFAOYSA-N 0.000 claims description 2
- GBPMHVWWNARLJZ-UHFFFAOYSA-N 1,1-bis(2-hydroxyethyl)-3-propylurea Chemical compound CCCNC(=O)N(CCO)CCO GBPMHVWWNARLJZ-UHFFFAOYSA-N 0.000 claims description 2
- BQMXKMPREFOYHS-UHFFFAOYSA-N 1,1-bis(2-hydroxyethyl)urea Chemical compound OCCN(C(=O)N)CCO BQMXKMPREFOYHS-UHFFFAOYSA-N 0.000 claims description 2
- SSZYXOKKPYHGLM-UHFFFAOYSA-N 1,3-dihydroxypropan-2-ylurea Chemical compound NC(=O)NC(CO)CO SSZYXOKKPYHGLM-UHFFFAOYSA-N 0.000 claims description 2
- WGFQARDLDGTVKH-UHFFFAOYSA-N 1-(1,3-dihydroxypropan-2-yl)-3-(2-hydroxyethyl)urea Chemical compound OCCNC(=O)NC(CO)CO WGFQARDLDGTVKH-UHFFFAOYSA-N 0.000 claims description 2
- SMEJDOFWKJVFCT-UHFFFAOYSA-N 1-(1-hydroxy-2-methylpropan-2-yl)-3-methylurea Chemical compound CNC(=O)NC(C)(C)CO SMEJDOFWKJVFCT-UHFFFAOYSA-N 0.000 claims description 2
- MEEMWRUUCUSUTN-UHFFFAOYSA-N 1-ethyl-3-(2-hydroxyethyl)urea Chemical compound CCNC(=O)NCCO MEEMWRUUCUSUTN-UHFFFAOYSA-N 0.000 claims description 2
- SYCFORXNZREGSA-UHFFFAOYSA-N 1-methyl-1-(1,3,4,5,6-pentahydroxyhexan-2-yl)urea Chemical compound NC(=O)N(C)C(CO)C(O)C(O)C(O)CO SYCFORXNZREGSA-UHFFFAOYSA-N 0.000 claims description 2
- VHEYHMGSWDZXEN-UHFFFAOYSA-N 2-hydroxypropylurea Chemical compound CC(O)CNC(N)=O VHEYHMGSWDZXEN-UHFFFAOYSA-N 0.000 claims description 2
- DNPHEDNKXRMPAX-UHFFFAOYSA-N 3-hydroxypropylurea Chemical compound NC(=O)NCCCO DNPHEDNKXRMPAX-UHFFFAOYSA-N 0.000 claims description 2
- TXDXRHGRYPYKHB-UHFFFAOYSA-N 3-tert-butyl-1-(2-hydroxyethyl)-1-(2-hydroxypropyl)urea Chemical compound CC(O)CN(CCO)C(=O)NC(C)(C)C TXDXRHGRYPYKHB-UHFFFAOYSA-N 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- IVSHBCMTAKLBIE-UHFFFAOYSA-N [1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]urea Chemical compound NC(=O)NC(CO)(CO)CO IVSHBCMTAKLBIE-UHFFFAOYSA-N 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- GRHQBTVCBZRVCM-UHFFFAOYSA-N 1,1,3,3-tetrakis(2-hydroxyethyl)urea Chemical compound OCCN(CCO)C(=O)N(CCO)CCO GRHQBTVCBZRVCM-UHFFFAOYSA-N 0.000 claims 1
- QJJLMANJJKBSNN-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexylurea Chemical compound NC(=O)NCC(O)C(O)C(O)C(O)CO QJJLMANJJKBSNN-UHFFFAOYSA-N 0.000 claims 1
- IWJFGRNIFIABLP-UHFFFAOYSA-N 2,3-dihydroxypropylurea Chemical compound NC(=O)NCC(O)CO IWJFGRNIFIABLP-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 9
- 210000004877 mucosa Anatomy 0.000 abstract description 6
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 235000019419 proteases Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 210000002510 keratinocyte Anatomy 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 235000019160 vitamin B3 Nutrition 0.000 description 6
- 239000011708 vitamin B3 Substances 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- 229940061720 alpha hydroxy acid Drugs 0.000 description 5
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 5
- 150000001277 beta hydroxy acids Chemical class 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 235000005152 nicotinamide Nutrition 0.000 description 5
- 239000011570 nicotinamide Substances 0.000 description 5
- 229960003966 nicotinamide Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960003471 retinol Drugs 0.000 description 5
- 235000020944 retinol Nutrition 0.000 description 5
- 239000011607 retinol Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- 235000002906 tartaric acid Nutrition 0.000 description 5
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 4
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 241001070941 Castanea Species 0.000 description 4
- 235000014036 Castanea Nutrition 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 240000001439 Opuntia Species 0.000 description 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 244000223014 Syzygium aromaticum Species 0.000 description 4
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000736 corneocyte Anatomy 0.000 description 4
- 210000001047 desmosome Anatomy 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 229960002510 mandelic acid Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000003908 Cathepsin D Human genes 0.000 description 3
- 108090000258 Cathepsin D Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 229930003537 Vitamin B3 Natural products 0.000 description 3
- 206010048218 Xeroderma Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229940067599 ascorbyl glucoside Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000001530 keratinolytic effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 150000003460 sulfonic acids Chemical class 0.000 description 3
- 239000012815 thermoplastic material Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- SBLKVIQSIHEQOF-OWOJBTEDSA-N (e)-octadec-9-enedioic acid Chemical compound OC(=O)CCCCCCC\C=C\CCCCCCCC(O)=O SBLKVIQSIHEQOF-OWOJBTEDSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QJBNLLPVVWIQAL-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O QJBNLLPVVWIQAL-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- BMLMGCPTLHPWPY-UHFFFAOYSA-N 2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical class OC(=O)C1CSC(=O)N1 BMLMGCPTLHPWPY-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 102000004092 Amidohydrolases Human genes 0.000 description 2
- 108090000531 Amidohydrolases Proteins 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 102000035101 Aspartic proteases Human genes 0.000 description 2
- 108091005502 Aspartic proteases Proteins 0.000 description 2
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 2
- 102100026540 Cathepsin L2 Human genes 0.000 description 2
- 101710169274 Cathepsin L2 Proteins 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- 244000025221 Humulus lupulus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 241000238413 Octopus Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007957 coemulsifier Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000005489 elastic deformation Effects 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940031575 hydroxyethyl urea Drugs 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000035984 keratolysis Effects 0.000 description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VADSVXSGIFBZLI-IBEHDNSVSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(2-methoxy-4-prop-2-enylphenoxy)oxane-3,4,5-triol Chemical compound COC1=CC(CC=C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VADSVXSGIFBZLI-IBEHDNSVSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- KWEAIXVWPDMXCR-FOCLMDBBSA-N (e)-hexadec-8-ene Chemical compound CCCCCCC\C=C\CCCCCCC KWEAIXVWPDMXCR-FOCLMDBBSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZGLXBKOIZOVYND-UHFFFAOYSA-N 1,1-bis(2-hydroxypropyl)urea Chemical compound CC(O)CN(C(N)=O)CC(C)O ZGLXBKOIZOVYND-UHFFFAOYSA-N 0.000 description 1
- UBZFJRDOTBGVAY-UHFFFAOYSA-N 1,3-bis(2-hydroxypropyl)urea Chemical compound CC(O)CNC(=O)NCC(C)O UBZFJRDOTBGVAY-UHFFFAOYSA-N 0.000 description 1
- SRQZUAPSTKOCBW-UHFFFAOYSA-N 1-dodecanoylpyrrolidin-2-one Chemical compound CCCCCCCCCCCC(=O)N1CCCC1=O SRQZUAPSTKOCBW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XYTHHAXRVHHXKO-JIUYZRCGSA-N 18-[(2r,3s,4r,5r)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxyoctadecanoic acid;ethanol Chemical compound CCO.COC1O[C@H](CO)[C@@H](OCCCCCCCCCCCCCCCCCC(O)=O)[C@H](O)[C@H]1O XYTHHAXRVHHXKO-JIUYZRCGSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- OIALAIQRYISUEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]e Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO OIALAIQRYISUEV-UHFFFAOYSA-N 0.000 description 1
- IXIGWKNBFPKCCD-UHFFFAOYSA-N 2-hydroxy-5-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 IXIGWKNBFPKCCD-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- NTBOCVZFBYLHFB-ROLXFIACSA-N 3-[(4s)-4-amino-4-carboxybutanoyl]-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N1C(C(O)=O)CSC1=O NTBOCVZFBYLHFB-ROLXFIACSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- ULGJWNIHLSLQPZ-UHFFFAOYSA-N 7-[(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-n-[2-(1h-indol-3-yl)ethyl]heptanamide Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCC(=O)NCCC=3C4=CC=CC=C4NC=3)=C21 ULGJWNIHLSLQPZ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 108700023155 Aspartoacylases Proteins 0.000 description 1
- 108010023546 Aspartylglucosylaminase Proteins 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 102000004958 Caspase-14 Human genes 0.000 description 1
- 108090001132 Caspase-14 Proteins 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 102000004178 Cathepsin E Human genes 0.000 description 1
- 108090000611 Cathepsin E Proteins 0.000 description 1
- 102100025975 Cathepsin G Human genes 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 101710178430 Cathepsin L-like Proteins 0.000 description 1
- 108090000751 Ceramidases Proteins 0.000 description 1
- 102000004201 Ceramidases Human genes 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 244000182633 Cinchona succirubra Species 0.000 description 1
- 235000006768 Cinchona succirubra Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000011799 Desmoglein Human genes 0.000 description 1
- 108050002238 Desmoglein Proteins 0.000 description 1
- 102000005708 Desmoglein 1 Human genes 0.000 description 1
- 108010045579 Desmoglein 1 Proteins 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 108010026752 Formamidase Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 102100038298 Kallikrein-14 Human genes 0.000 description 1
- 101710115806 Kallikrein-14 Proteins 0.000 description 1
- 102100034868 Kallikrein-5 Human genes 0.000 description 1
- 101710176223 Kallikrein-5 Proteins 0.000 description 1
- 102100034867 Kallikrein-7 Human genes 0.000 description 1
- 101710176222 Kallikrein-7 Proteins 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 125000001992 L-gamma-glutamyl group Chemical group N[C@@H](CCC(=O)*)C(=O)O 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 102000001696 Mannosidases Human genes 0.000 description 1
- 108010054377 Mannosidases Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010037943 N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- RSYYQCDERUOEFI-JTQLQIEISA-N N-benzoyl-L-arginine Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 RSYYQCDERUOEFI-JTQLQIEISA-N 0.000 description 1
- 208000011219 Netherton syndrome Diseases 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- UCFWQUACYISCRE-UHFFFAOYSA-N OC(CNC(=O)N)C(C(C(CO)O)O)O.OC(CNC(=O)N)CO Chemical compound OC(CNC(=O)N)C(C(C(CO)O)O)O.OC(CNC(=O)N)CO UCFWQUACYISCRE-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000007279 Papillon-Lefevre Disease Diseases 0.000 description 1
- 208000035884 Papillon-Lefèvre syndrome Diseases 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241001077909 Sigesbeckia Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 241001092387 Spiraea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 235000013030 Voandzeia subterranea Nutrition 0.000 description 1
- 244000170226 Voandzeia subterranea Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- IPVNPUHVCZJVOI-VJSFXXLFSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 IPVNPUHVCZJVOI-VJSFXXLFSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 108010003977 aminoacylase I Proteins 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 102000018919 aspartoacylase Human genes 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229940004048 beta-sitosteryl sulfate Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- VIEXQFHKRAHTQS-UHFFFAOYSA-N chloroselanyl selenohypochlorite Chemical compound Cl[Se][Se]Cl VIEXQFHKRAHTQS-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- SUXVWSIPTXXPOZ-UHFFFAOYSA-N demethyleugenol beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(CC=C)C=C1O SUXVWSIPTXXPOZ-UHFFFAOYSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002061 ecdysteroids Chemical class 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- MFGZXPGKKJMZIY-UHFFFAOYSA-N ethyl 5-amino-1-(4-sulfamoylphenyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC=C(S(N)(=O)=O)C=C1 MFGZXPGKKJMZIY-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- LIEMWVYKRWIQMX-UHFFFAOYSA-N eugenyl beta-D-glucopyranoside Natural products COC1=CC=C(CC=C)C=C1OC1C(O)C(O)C(O)C(CO)O1 LIEMWVYKRWIQMX-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical class CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 description 1
- 108010075526 keratohyalin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 108010003855 mesentericopeptidase Proteins 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 235000020014 märzen Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940119519 peg-32 stearate Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010086105 peptidyl-glutaminase Proteins 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 235000020746 red clover extract Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 235000004239 secoisolariciresinol Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940045875 sodium pidolate Drugs 0.000 description 1
- CRPCXAMJWCDHFM-DFWYDOINSA-M sodium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)[C@@H]1CCC(=O)N1 CRPCXAMJWCDHFM-DFWYDOINSA-M 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- OHOTVSOGTVKXEL-UHFFFAOYSA-K trisodium;2-[bis(carboxylatomethyl)amino]propanoate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C(C)N(CC([O-])=O)CC([O-])=O OHOTVSOGTVKXEL-UHFFFAOYSA-K 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Drugs [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940100142 zinc pidolate Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Materials Engineering (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
表皮と真皮の間の結合は、真皮表皮接合部によりもたらされる。
R1、R2、R3およびR4はそれぞれ、互いに独立に、水素原子、C1〜C4アルキル基、または1〜5個のヒドロキシル基を含むことができるC2〜C6ヒドロキシアルキル基を表し、R1からR4基の少なくとも1つはヒドロキシアルキル基を表す]、ならびにこれらの塩、これらの溶媒和物およびこれらの異性体の美容使用に関する。
− 好ましくは、R1はC2〜C6ヒドロキシアルキル基を示し、R2、R3およびR4は、それぞれ互いに独立に、水素原子またはC1〜C4アルキル基を示し、
− 好ましくは、R1は、1〜5個のヒドロキシル基、特に1個のヒドロキシル基を含むC2〜C6ヒドロキシアルキル基を示し、R2、R3およびR4は水素原子を示し、
− より好ましくは、R1は、1個のヒドロキシル基を含むC2〜C4ヒドロキシアルキル基を示し、R2、R3およびR4は水素原子を示す。
好ましくは、式(I)の化合物は、N−(2−ヒドロキシエチル)尿素である。
・ 5%の活性剤を含有する製剤化した生成物を用いて、制御された環境室下、コルネオデスモシンの分解をテストすることによる、落屑促進力:このテストにより、コルネオデスモシンのタンパク質分解を緩和する、製剤化した活性剤の能力を評価することができる。
・ 「角質溶解」の潜在能力:
ケラチン可溶化(「角質溶解」)テスト:このテストは、尿素とその誘導体の変性能力を例証することに相当する。分子の、SCのケラチンの可溶化効果は、電気泳動ゲルにおいてモニターされる。
・ SCの酸プロテアーゼの「活性化」の可能性:このテストでは、ある条件下において、ある表皮プロテアーゼのタンパク質溶解可能性が増加可能であることを示すことができる。
・ カリクレイン(kallikrein)ファミリーのセリンプロテアーゼ、たとえば、カリクレイン5、7、または14;
・ アスパラギン酸プロテアーゼ、たとえばカテプシン(Cathepsin)D,E,またはSASパーゼ(Locuslink 151516)、または文献:WO 04/007548に記載されたプロテアーゼ;
・ システインプロテアーゼ、たとえばカテプシンB,H,L,L2,カルパインまたはカスパーゼ14;
・ メタロプロテアーゼ、たとえばカルボキシペプチダーゼ。
好ましくは、本発明の組成物は、皮膚または粘膜に塗布される。
− 剥離を促進することにより落屑に直接的に作用し得るあらゆる化合物、例えば、β-ヒドロキシ酸、特にサリチル酸とその誘導体(5-n-オクタノイルサリチル酸を含む);α-ヒドロキシ酸、例えばグリコール酸、クエン酸、乳酸、酒石酸、リンゴ酸またはマンデル酸;尿素;ゲンチシン酸;オリゴフコース;ケイ皮酸;シダレエンジュ(Saphora japonica)の抽出物;レスベラトロル;およびジャスモン酸のいくつかの誘導体;または、
− 落屑またはコルネオデスモソーム(corneodesmosomes)の分解に関与する酵素、グリコシダーゼ、他のプロテアーゼ(トリプシン、キモトリプシン様)の角質層キモトリプシン酵素(SCCE)に作用し得るあらゆる化合物を意味する。鉱物塩をキレートする薬剤:EDTA;N-アシル-N,N’,N’-エチレンジアミン三酢酸;アミノスルホン化合物、特に(N-2-ヒドロキシエチルピペラジン-N-2-エタン)スルホン酸(HEPES);2-オキソチアゾリジン-4-カルボン酸の誘導体(プロシステイン);グリシンのようなタイプのα-アミノ酸の誘導体(EP-0,852,949に記載のもの、Trilon Mの商品名でBASFから市販されているメチルグリシン二酢酸ナトリウム);蜂蜜;O-オクタノイル-6-D-マルトースおよびN-アセチルグルコサミンのような糖誘導体;栗の抽出物、たとえばSILAB社からRecoverine(登録商標)の名称で市販されているもの、ウチワサボテンの抽出物、たとえば、SILAB社からExfolactiveの商品名で市販されているもの、または、Degussa社から市販されているPhytosphingosine SLC(登録商標)を挙げることができる。
Xは、−OH基又は−NHR2基を示し、R1及びR2は、同一でも異なっていてもよく、
−水素原子、
−少なくとも1つの−OR基、及び/又は少なくとも1つの−COOR基、及び/又は少なくとも1つの−NHR基、及び/又は少なくとも1つの−SR基、及び/又は少なくとも1つの−R基(ここで、Rは水素又は直鎖又は分枝C1−C4アルキルを示す)で任意に置換された直鎖又は分枝C1−C8アルキル基、
−COR3基[ここで、R3は、少なくとも1つの−OR基、及び/又は少なくとも1つの−COOR基、及び/又は少なくとも1つの−NHR基、及び/又は少なくとも1つの−SR基、及び/又は少なくとも1つの−R基(ここで、Rは水素又は直鎖又は分枝C1−C4アルキルを示す)で任意に置換された直鎖又は分枝C1−C8アルキル基を示す]、
−少なくとも1つの−OR基、及び/又は少なくとも1つの−COOR基、及び/又は少なくとも1つの−NHR基、及び/又は少なくとも1つの−SR基、及び/又は少なくとも1つの−R基(ここで、Rは水素又は直鎖又は分枝C1−C4アルキルを示す)で任意に置換された、ベンゼンまたはヘテロ環アラルキルまたはアリール基を示す)。
− 角質層の保湿性を維持するためにバリア機能に作用する化合物または閉塞性化合物であって、例えばセラミド、スフィンゴイド系化合物、レシチン、グリコスフィンゴ脂質、リン脂質、コレステロールとその誘導体、フィトステロール(スチグマステロール、β−シトステロールまたはカンポステロール)、必須脂肪酸、1,2-ジアシルグリセロール、4-クロマノン、五環式トリテルペン、例えばウルソール酸、ワセリンおよびラノリン;
− または、角質層の水分含量を直接増大させる化合物であって、例えば、スレアロースとその誘導体、ヒアルロン酸とその誘導体、グリセロール、ペンタンジオール、ナトリウムピドラート、セリン、キシリトール、乳酸ナトリウム、ポリグリセリルアクリラート、エクトインとその誘導体、キトサン、オリゴ糖および多糖、環状炭酸塩、N-ラウロイル-ピロリドンカルボン酸およびN−α−ベンゾイル-L-アルギニン;特許文献:WO 02/051828に記載されているような、Hepes、またはC-グリコシド化誘導体;
− または、皮脂分泌腺を活性化する化合物であって、例えばステロイド誘導体(DHEA、7−酸化及び/または17−アルキル化誘導体、およびサポゲニン)、ジヒドロジャスモン酸メチル、およびビタミンD及びその誘導体
を意味するものと理解される。後者のカテゴリーの化合物は、より特に、成熟した、または更に成熟した、たとえば55または60歳を超える人の皮膚に適用するのに好適である。
− メタロプロテイナーゼ(マトリックスメタロプロテイナーゼまたはMMP)、特にMMP1、2、3または9などの阻害に作用するもの、たとえば、レチノイドおよび誘導体、オリゴペプチドおよびリポペプチド、リポアミノ酸、Coletica社により商標名Collalift(登録商標)として販売されている麦芽抽出物;ブルーベリーまたはローズマリーの抽出物;リコペン;イソフラボン、これらの誘導体またはこれらを含む植物抽出物、特に、ダイズ抽出物(Ichimaru Pharcos社により商標名Flavosterone SB(登録商標)として販売されている)、レッドクローバー抽出物(たとえば、Sederma社により商標名「Sterocare(登録商標)」として販売されている)、亜麻、葛根またはセージの抽出物;ウコン(Curcuma longa)の抽出物;あるいはメナモミ(Siegesbeckia)抽出物(たとえば、Sederma社により販売されている)を挙げることができ;
− あるいは、白血球エラスターゼまたはカテプシンGなどのある種のセリンプロテアーゼの阻害に作用するもの、たとえば、Laboratoires Serobiologiques社により商標名Parelastyl(登録商標)として販売されているマメ科植物(エンドウ(Pisum sativum))種子のペプチド抽出物;ヘパリノイド;及び(2−[アセチル(3−(トリフルオロメチル)フェニル)アミノ]−3−メチルブチリルアミノ]酢酸などのプソイドジペプチドを挙げることができる。
・レチノイド、特にレチノール;
・硫黄と硫黄含有誘導体;
・亜鉛塩、例えば乳酸亜鉛、グルコン酸亜鉛、ピドール酸亜鉛、カルボン酸亜鉛、サリチル酸亜鉛、および/またはシステアリン酸亜鉛;
・セレニウム塩化物;
・ビタミンB6またはピリドキシン;
・特にSEPPIC社によってSepicontrol A5(登録商標)という商品名で販売されているカプリロールグリシン、サルコシンおよび桂皮の抽出物の混合物;
・特にBiotech Marine社によってPhlorogine(登録商標)という商品名で販売されているラミナリア甘味薬の抽出物;
・特にSilab社によってSebonormine(登録商標)という商品名で販売されているスピラエアウルマリアの抽出物;
・例えば、マルゼン社によって全て販売されている種:アルニカモンタナ(Arnica montana)、アカナイキ(Cinchona succirubra)、チョウジ(Eugenia caryophyllata)、ホップ(Humulus lupulus)、セイヨウオトギリソウ(Hypericum perforatum)、セイヨウハッカ(Mentha piperita)、マンネンロウ(Rosmarinus officinalis)、サルビヤ(Salvia officinalis)およびタチジャコウソウ(Thymus vulgaris)の植物抽出物;
・特にEuromed社によって販売されているノコギリヤシ(Serenoa repens)の抽出物;
・シリブム(Silybum)属の植物の抽出物;
・オイゲノールおよびオイゲニルグルコシドを含むチョウジ(Eugenia caryophyllata)の抽出物。
前記工程(ii)中、落屑剤は、10%以上、特に約20から50%の全濃度で適用し、5分から6時間の間、好ましくは、5分から30分の間、皮膚と接触させるであろう。
− 上記で定義した式(I)の少なくとも1つの化合物をまたはそれを含有する組成物を含む第1成分、
− プロテアーゼ、リパーゼ、およびグリコシダーゼから選択された少なくとも1つの剤を含有する第2成分
を適用することからなるケラチン物質の美容処理方法に関し、これら2つの成分は同時に、合同して、または順次に、皮膚、粘膜、または表面成長体に適用することからなる。
− 上記で定義した式(I)の少なくとも1つの化合物を含有する第1成分、
− プロテアーゼ、リパーゼ、およびグリコシダーゼから選択された少なくとも1つの剤を含有する第2成分を含有する、キット形態の美容組成物または美容剤であって、これら2つの成分は同時に、合同して、または順次に、皮膚、粘膜、または表面成長体に適用される、美容組成物または美容剤に関する。
i)少なくとも1つの区画を区切る容器であって、封止部で封止される容器;および
ii)前記区画内に収容された組成物を含有する美容セットに関する。
または、容器は、非熱可塑性材料、特にガラスまたは金属(または合金)で形成されていてもよい。
a)アシッドプロテアーゼを含有する角質層抽出物を調製し、
b)試験化合物または尿素を含有する混合物を得るために、ラベルしたタンパク質基質を種々の濃度の試験化合物と、および、タンパク質分解濃度の尿素と混合し、
c)試験化合物、または尿素を含有する反応混合物を得るために、前記工程a)で得られた抽出物のフラクションを、工程b)の最後に得られた種々の混合物と接触させ、または、対照を得るためにラベルしたカゼイン基質と接触させ、
d)インキュベーション後、対照のものと、種々の反応混合物中のタンパク質分解反応を比較し、
e)タンパク質分解強度が対照のものよりも大きい化合物を選択することからなる工程を含有する。
制御した環境試験槽におけるコルネオデスモシンの分解
分子を中性ベースArlacel/Myrj中、製剤化した。プロダクトを、規定の温度、湿度、およびインキュベーション期間の条件下、ニスを塗ったストリッピングと接触させる。コルネオデスモシンをインキュベーション後、免疫検出法によりアッセイする。これは、電気泳動分離および膜への移送後、免疫ブロット法で行われる。抗体G3619を用いて特定のラベルをつけた後、化学発光により可視化される。
乾燥した足の裏の皮膚にニスを塗ったストリッピングから、3X3.5cm2の長方形を切り出す。これらを42mgの各プロダクト(4mg/cm2)で処理する。対照およびアッセイは平行して行う。アッセイは、37℃、70%の相対湿度下、5日間インキュベートする。対照は、−20℃で5日間保持する。各サンプルに対して、アセトンパウダーを作って秤量する。タンパク質を100μlの完全Laemmliバッファーで抽出する。これらをBradford法によりアッセイする。各サンプルのタンパク質レベルを調節すると、種々のサンプルの直接比較ができるであろう。
結果は、行われた2回の実験の平均で示す。
結果は、対照−80℃に対する残存コルネオデスモシンの割合として示される。
前記割合が低くなればなるほど、分解がより高くなり、落屑促進効果がより高くなる。
尿素の、角質溶解性タンパク質の変性効果が知られている。尿度誘導体を用いて可溶化することが困難である、SCのタンパク質およびケラチンに対して溶解効果を例証するために、最適化が行われた。
ボランティアの足の裏の角質層のアセトンパウダー、30mgを調製し、3mlの水+2%CHAPS(双性イオン洗浄剤)と、室温で10分間接触させる。混合物を次いで、陶器装置中ですりつぶし、15000gで10分間遠心分離する。上澄みを除去する。この方法によって、結果の解釈に邪魔になるであろう、非常に溶解性のあるケラチンおよびタンパク質を除去することができる。ペレットを300μlの水+CHAPSに取り込み、20μlを10エッペンドルフ(Eppendorf)チューブに分配する。
テストすべき各分子を水+2%CHAPS中、2Mで調製する。
N-(2-ヒドロキシエチル)尿素組成物(Hydrovance(登録商標))は、低いMWバンドが現れるため、尿素とは区別可能であり、すなわち、より良好に抽出されたタンパク質、インキュベーション中に発生したフラグメントとは、区別可能である。
SC(角質層)のある種のアシッドプロテアーゼを活性化する特性を評価する。この活性の測定は、Enzchekキット(Molecular Probes)を用いて蛍光分析アッセイにより行われる。このプロトコールは、加水分解すると蛍光を示すBodiphfl-カゼイン基質を用いる。この放出された蛍光は、プロテアーゼ活性に直接比例する。蛍光を、750V、485nmで励起し、535nmで発光する分光蛍光計により、96ウエルプレートおいて直接読み取る。
分子を、pH5.0で、0.1M酢酸バッファー中、0,1,2、および4Mで調製する。酵素抽出物をアセトンパウダーから調製する。2mlのPBSバッファー+0.1%トリトンX100を、200mgの角質層アセトンパウダーとともに砕いた氷中、1時間接触させる。混合物を次いで、陶器装置中ですりつぶし、次いで、4℃、15000gで10分間遠心分離する。上澄みを回収する。1/200希釈したEnzchek基質を、分子を含む各溶液に取り込む。このアッセイを3回繰り返す。
結果は添付の図面に示す。
ケアークリーム:
トリエタノールアミン ... 0.3300
水(および)ヒドロキシエチル尿素 ... 10.0000
水素添加ポリイソブテン ... 5.0000
プロピルパラベン ... 0.1000
メチルパラベン ... 0.2000
カルボメール ... 0.3000
シクロペンタシロキサン ...15.0000
水 ... 62.0700
PEG-50ステアレート ...2.5000
グリセリルステアレート(及び)PEG−100ステアレート ... 2.5000
セチルアルコール ...1.0000
ステアリルアルコール ...1.0000
水(および)ヒドロキシエチル尿素 ... 10.0000
サラノキのシードバター ... 2.0000
アプリコット核油 ... 6.0000
クロルヘキシジン ジグルコネート ... 0.3000
プロピルパラベン ... 0.1000
メチルパラベン ... 0.2500
キサンタンガム ... 0.2500
ポリアクリルアミド(及び)C13-14イソパラフィン(及び)ラウレス−7 ... 1.0000
シクロヘキサシロキサン ... 10.0000
水 ... 64.1000
メチルグルコース セスキステアレート ... 2.0000
PEG−20 メチルグルコース セスキステアレート ... 2.0000
ステアリルアルコール(及び)セレアルス(cerearth)−20 ... 2.0000
Claims (21)
- 式(I)において、R1はC2〜C6ヒドロキシアルキル基を示し、R2、R3およびR4は、互いに独立に、水素原子またはC1〜C4アルキル基を示すことを特徴とする、請求項1に記載の少なくとも1つの式(I)の化合物の使用。
- 式(I)において、R1は、1〜5個のヒドロキシル基を含むC2〜C6ヒドロキシアルキル基を示し、R2、R3およびR4は、水素原子を示すことを特徴とする、請求項1または2に記載の使用。
- 式(I)において、R1は、1個のヒドロキシル基を含むC2〜C6ヒドロキシアルキル基を示すことを特徴とする、請求項1から3のいずれか一項に記載の使用。
- R1は、1個のヒドロキシル基を含むC2〜C4ヒドロキシアルキル基を示し、R2、R3およびR4は、水素原子を示すことを特徴とする、請求項1から4のいずれか一項に記載の使用。
- 式(I)の化合物が、N−(2−ヒドロキシエチル)尿素;N−(2−ヒドロキシプロピル)尿素;N−(3−ヒドロキシプロピル)尿素;N−(2,3−ジヒドロキシプロピル)尿素;N−(2,3,4,5,6−ペンタヒドロキシヘキシル)尿素;N−メチル−N−(1,3,4,5,6−ペンタヒドロキシ−2−ヘキシル)尿素;N−メチル−N'−(1−ヒドロキシ−2−メチル−2−プロピル)尿素;N−(1−ヒドロキシ−2−メチル−2−プロピル)尿素;N−(1,3−ジヒドロキシ−2−プロピル)尿素;N−[トリス(ヒドロキシメチル)メチル]尿素;N−エチル−N'−(2−ヒドロキシエチル)尿素;N,N−ビス(2−ヒドロキシエチル)尿素;N,N'−ビス(2−ヒドロキシエチル)尿素;N,N−ビス(2−ヒドロキシプロピル)尿素;N,N'−ビス(2−ヒドロキシプロピル)尿素;N,N−ビス(2−ヒドロキシエチル)−N'−プロピル尿素;N,N−ビス(2−ヒドロキシプロピル)−N'−(2−ヒドロキシエチル)尿素;N−(tert−ブチル)−N'−(2−ヒドロキシエチル)−N'−(2−ヒドロキシプロピル)尿素;N−(1,3−ジヒドロキシ−2−プロピル)−N'−(2−ヒドロキシエチル)尿素;N,N−ビス(2−ヒドロキシエチル)−N',N'−ジメチル尿素;N,N,N',N'−テトラキス(2−ヒドロキシエチル)尿素;N',N'−ビス(2−ヒドロキシエチル)−N',N'−ビス(2−ヒドロキシプロピル)尿素;ならびにこれらの混合物から選択されることを特徴とする、請求項1から5のいずれか一項に記載の使用。
- 前記化合物が、コルネオデスモシンの分解を刺激し、および/または、式(I)の化合物が、ケラチン分解活性を有し、および/または、式(I)の化合物が、角質層のプロテアーゼ、特にアシッドプロテアーゼの活性を刺激することを特徴とする、請求項1から7のいずれか一項に記載の使用。
- 前記組成物が、剥離組成物であることを特徴とする、請求項1から10のいずれか一項に記載の式(I)の化合物の使用。
- 前記組成物が、皮膚及び/または頭皮をクレンジングするためのものであることを特徴とする、請求項1から8のいずれか一項に記載の使用。
- 前記組成物が、皮膚及び/または唇の表面状態を改善するためのものであることを特徴とする、請求項1から9のいずれか一項に記載の使用。
- 落屑障害に関連した徴候のトリートメント用組成物を調製するための、請求項1から6のいずれか一項に定義した式(I)の少なくとも1つの化合物の使用。
- 前記組成物が、魚鱗癬、過角化症、乾皮症、乾癬、アトピー性皮膚炎、アクネ、およびフケから選択された少なくとも1つの皮膚障害をトリートメントための、および/または外傷治癒を促進するためのものであることを特徴とする、請求項11に記載の使用。
- 前記組成物が、皮膚及び/または粘膜及び/または表面成長体に局所適用するためのものであることを特徴とする、請求項1から12のいずれか一項に記載の使用。
- 前記組成物が、式(I)の化合物とは相違する少なくとも1つの落屑刺激剤をさらに含有することを特徴とする、請求項1から17のいずれか一項に記載の使用。
- 前記組成物が、プロテアーゼ、グリコシダーゼ、およびリパーゼから選択された少なくとも1つの化合物をさらに含有し、及び/または、前記組成物が、保湿剤、有害なプロテアーゼの活性を減少させる又は阻害する薬剤、表皮分化刺激剤および抗脂漏剤から選択された少なくとも1つの化合物をさらに含有することを特徴とする、請求項1から14のいずれか一項に記載少なくとも1つの式(I)の化合物の使用。
- 少なくとも1つの式(I)の化合物または請求項1から15のいずれか一項に記載のものを含有する組成物を、皮膚または粘膜に適用することを特徴とする、顔の輝きを促進する及び/または皮膚及び/または粘膜の表面凹凸を減少させるための美容処理方法。
- 少なくとも2つの成分:
− 請求項1ないし15のいずれか1項に記載の式(I)の少なくとも1つの化合物を含有する第1成分、
− プロテアーゼ、リパーゼ、およびグリコシダーゼから選択された少なくとも1つの剤を含有する第2成分
を適用することからなり、これら2つの成分は同時に、合同して、または順次に、皮膚、粘膜、または表面成長体に適用することからなることを特徴とする、ケラチン物質の美容処理方法。 - 少なくとも2つの成分:
− 請求項1ないし15のいずれか1項に記載の式(I)の少なくとも1つの化合物を含有する第1成分、
− プロテアーゼ、リパーゼ、およびグリコシダーゼから選択された少なくとも1つの剤を含有する第2成分を含有する、キット形態の美容剤であって、これら2つの成分は同時に、合同して、または順次に、皮膚、粘膜、または表面成長体に適用されることを特徴とする、美容剤。 - a)少なくとも1つの区画を区切る容器であって、封止部で封止される容器;および
b)前記区画内に収容された組成物を含有し、前記組成物は、請求項1ないし15に記載のものであることを特徴とする、美容セット。 - 再構成した皮膚を調製するための、請求項1ないし7のいずれか1項に記載の式(I)の少なくとも1つの化合物の使用。
- a)アシッドプロテアーゼを含有する角質層抽出物を調製し、
b)試験化合物または尿素を含有する混合物を得るために、ラベルしたタンパク質基質を種々の濃度の試験化合物と、および、タンパク質分解濃度の尿素と混合し、
c)試験化合物、または尿素を含有する反応混合物を得るために、前記工程a)で得られた抽出物のフラクションを、工程b)の最後に得られた種々の混合物と接触させ、または、対照を得るためにラベルしたカゼイン基質と接触させ、
d)インキュベーション後、対照のものと、種々の反応混合物中のタンパク質分解反応を比較し、
e)タンパク質分解強度が対照のものよりも大きい化合物を選択することからなる工程を含有する、落屑化合物の選択方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0552189A FR2888494B1 (fr) | 2005-07-13 | 2005-07-13 | Utilisation de composes d'uree pour favoriser la desquamation |
FR0552189 | 2005-07-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007023038A true JP2007023038A (ja) | 2007-02-01 |
JP2007023038A5 JP2007023038A5 (ja) | 2009-08-20 |
JP5431635B2 JP5431635B2 (ja) | 2014-03-05 |
Family
ID=36218114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006192113A Active JP5431635B2 (ja) | 2005-07-13 | 2006-07-12 | 落屑を促進するための尿素化合物の使用 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1743623B1 (ja) |
JP (1) | JP5431635B2 (ja) |
ES (1) | ES2593040T3 (ja) |
FR (1) | FR2888494B1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009256255A (ja) * | 2008-04-17 | 2009-11-05 | Pola Chem Ind Inc | クレンジング機能を有する皮膚外用剤 |
JP2014528417A (ja) * | 2011-09-30 | 2014-10-27 | イーエルシー マネージメント エルエルシー | 薄毛の出現を低減させるための方法 |
JP2014205667A (ja) * | 2013-04-14 | 2014-10-30 | シムライズ アーゲー | スキン/ヘアライトニング組成物 |
US9155768B2 (en) | 2011-09-30 | 2015-10-13 | Elc Management Llc | Regimen for reducing the appearance of thinning hair |
JP2017128560A (ja) * | 2016-01-14 | 2017-07-27 | 日本メナード化粧品株式会社 | 角栓分解促進剤 |
JP2021505664A (ja) * | 2017-12-04 | 2021-02-18 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 肌角質剥離促進用化粧用組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007054833A2 (en) * | 2005-11-14 | 2007-05-18 | L'oréal | Cosmetic use of a hydroxyalkylurea as an agent for treating desquamative conditions of the scalp; cosmetic treatment compositions and processes |
ES2336995B1 (es) | 2008-10-13 | 2011-02-09 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas. |
JP4608584B1 (ja) * | 2009-06-29 | 2011-01-12 | 株式会社資生堂 | 皮膚外用剤 |
WO2023052995A1 (en) * | 2021-09-30 | 2023-04-06 | L'oreal | Compositions with high urea content and methods for boosting actives |
FR3130147A1 (fr) * | 2021-12-15 | 2023-06-16 | L'oreal | Composition de rajeunissement de la peau à forte concentration en urée pour renforcer les actifs de soin de la peau |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2703185A1 (de) * | 1977-01-27 | 1978-08-10 | Henkel Kgaa | Kosmetische mittel mit einem gehalt an haut-feuchthaltemitteln |
JPH11139933A (ja) * | 1997-08-29 | 1999-05-25 | L'oreal Sa | 表皮から単離されたポリペプチドとその用途 |
JP2004517063A (ja) * | 2000-11-17 | 2004-06-10 | ロレアル | 2−オキソチアゾリジン−4−カルボン酸誘導体の剥離促進剤としての使用 |
JP2004520274A (ja) * | 2000-11-13 | 2004-07-08 | ロレアル | 少なくとも一のグリコシダーゼを含有する組成物、プロテアーゼを含有しない該組成物 |
US20040197299A1 (en) * | 2003-01-16 | 2004-10-07 | Societe L'oreal, S.A. | Topically applicable cosmetic/dermatological compositions comprising hydrolase polypeptides having amidase activity and/or products modulating the activity thereof |
WO2004093838A1 (en) * | 2003-04-24 | 2004-11-04 | L'oreal | Cosmetic peeling method using urea |
JP2005015454A (ja) * | 2003-06-26 | 2005-01-20 | Cosmo Products Kk | 炭酸ガス発生化粧品 |
JP2005170941A (ja) * | 2003-11-26 | 2005-06-30 | Natl Starch & Chem Investment Holding Corp | ヒドロキシアルキル尿素を使用する湿潤化効能の増加 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2816837A1 (fr) * | 2000-11-17 | 2002-05-24 | Oreal | Utilisation d'au moins un derive amino sulfonique dans une composition destinee a favoriser la desquamation de la peau |
US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
-
2005
- 2005-07-13 FR FR0552189A patent/FR2888494B1/fr not_active Expired - Fee Related
-
2006
- 2006-07-10 EP EP06116879.5A patent/EP1743623B1/fr active Active
- 2006-07-10 ES ES06116879.5T patent/ES2593040T3/es active Active
- 2006-07-12 JP JP2006192113A patent/JP5431635B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2703185A1 (de) * | 1977-01-27 | 1978-08-10 | Henkel Kgaa | Kosmetische mittel mit einem gehalt an haut-feuchthaltemitteln |
JPH11139933A (ja) * | 1997-08-29 | 1999-05-25 | L'oreal Sa | 表皮から単離されたポリペプチドとその用途 |
JP2004520274A (ja) * | 2000-11-13 | 2004-07-08 | ロレアル | 少なくとも一のグリコシダーゼを含有する組成物、プロテアーゼを含有しない該組成物 |
JP2004517063A (ja) * | 2000-11-17 | 2004-06-10 | ロレアル | 2−オキソチアゾリジン−4−カルボン酸誘導体の剥離促進剤としての使用 |
US20040197299A1 (en) * | 2003-01-16 | 2004-10-07 | Societe L'oreal, S.A. | Topically applicable cosmetic/dermatological compositions comprising hydrolase polypeptides having amidase activity and/or products modulating the activity thereof |
WO2004093838A1 (en) * | 2003-04-24 | 2004-11-04 | L'oreal | Cosmetic peeling method using urea |
JP2005015454A (ja) * | 2003-06-26 | 2005-01-20 | Cosmo Products Kk | 炭酸ガス発生化粧品 |
JP2005170941A (ja) * | 2003-11-26 | 2005-06-30 | Natl Starch & Chem Investment Holding Corp | ヒドロキシアルキル尿素を使用する湿潤化効能の増加 |
Non-Patent Citations (1)
Title |
---|
JPN6011045916; Chem Rev, vol.96, p.3147-3176 (1996) * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009256255A (ja) * | 2008-04-17 | 2009-11-05 | Pola Chem Ind Inc | クレンジング機能を有する皮膚外用剤 |
JP2014528417A (ja) * | 2011-09-30 | 2014-10-27 | イーエルシー マネージメント エルエルシー | 薄毛の出現を低減させるための方法 |
US9155768B2 (en) | 2011-09-30 | 2015-10-13 | Elc Management Llc | Regimen for reducing the appearance of thinning hair |
JP2017008045A (ja) * | 2011-09-30 | 2017-01-12 | イーエルシー マネージメント エルエルシー | 薄毛の出現を低減させるための方法 |
JP2014205667A (ja) * | 2013-04-14 | 2014-10-30 | シムライズ アーゲー | スキン/ヘアライトニング組成物 |
JP2017128560A (ja) * | 2016-01-14 | 2017-07-27 | 日本メナード化粧品株式会社 | 角栓分解促進剤 |
JP2021505664A (ja) * | 2017-12-04 | 2021-02-18 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 肌角質剥離促進用化粧用組成物 |
JP7186793B2 (ja) | 2017-12-04 | 2022-12-09 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 肌角質剥離促進用化粧用組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP1743623B1 (fr) | 2016-06-29 |
EP1743623A3 (fr) | 2010-04-14 |
EP1743623A2 (fr) | 2007-01-17 |
FR2888494B1 (fr) | 2014-03-14 |
JP5431635B2 (ja) | 2014-03-05 |
ES2593040T3 (es) | 2016-12-05 |
FR2888494A1 (fr) | 2007-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5431635B2 (ja) | 落屑を促進するための尿素化合物の使用 | |
US7999008B2 (en) | Urea compounds that promote desquamation | |
ES2492915T3 (es) | Utilización de compuestos de urea para luchar contra los signos del envejecimiento cutáneo | |
RU2169000C2 (ru) | Применение экстракта iridaceae, композиция, содержащая его и способ косметического лечения | |
JP4086867B2 (ja) | N−アシルアミノアミドファミリー化合物と少なくとも1種のマトリックスメタロプロテイナーゼ阻害剤の組み合わせを含む化粧品用又は皮膚用組成物 | |
JP4072433B2 (ja) | 2−オキソチアゾリジン−4−カルボン酸誘導体の剥離促進剤としての使用 | |
US8173144B2 (en) | Administration of urea compounds for combating signs of cutaneous aging | |
JP2008013564A (ja) | 少なくとも1のc−グリコシド誘導体の鎮静剤としての使用 | |
ES2693261T3 (es) | Uso de derivados de C-glicósido como agentes activos pro-descamantes | |
US20100189675A1 (en) | Cosmetic use of an imidopercarboxylic acid derivative as desquamating agent | |
JP4117774B2 (ja) | N−アシルアミノアミドファミリーのエラスターゼ阻害剤化合物と少なくとも1種の抗炎症剤化合物の組み合わせを含む化粧品用又は皮膚用組成物 | |
EP1889642B1 (fr) | Compositions cosmétiques associant un dérivé C-glycoside et un dérivé N-acylaminoamide | |
JP2009541477A (ja) | アスコルビン酸と組合せたc−グリコシド誘導体の化粧料としての使用 | |
JP2003055133A (ja) | N−アシルアミノアミドファミリーのエラスターゼ阻害剤と少なくとも1種の筋弛緩剤の組み合わせを含む化粧品用又は皮膚用組成物 | |
JP2007291119A (ja) | 少なくとも一のグリコシダーゼを含有する組成物、プロテアーゼを含有しない該組成物 | |
KR20200117951A (ko) | 피부 내의 기질 메탈로프로테이나아제를 억제하고 노화를 감소시키는 방법 및 관련 상승작용 조성물들 | |
RU2141310C1 (ru) | Активное начало косметического средства и косметическое средство (варианты) | |
KR100996560B1 (ko) | 프로테아제 활성화제를 포함하는 화장용 조성물 | |
JP2004217662A (ja) | アミダーゼ活性を有する加水分解酵素ファミリーの少なくとも1つのポリペプチドを含有し局所適用される組成物及び/又はその活性を調節可能な生成物 | |
JP2018168177A (ja) | マトリックスメタロプロテイナーゼを阻害して皮膚の老化を軽減する方法及び関連の相乗的組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090703 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090703 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120215 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120918 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130226 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130527 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130626 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130726 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5431635 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |